MELBOURNE, FL / ACCESSWIRE / March 3, 2022 / BioFuse Medical Technologies, Inc., an emerging medical device company with transformative tissue sealing and welding technology, today announced the appointment of Scott R. Sanders to the position of President.
“I am pleased to announce the addition of Scott Sanders to our team and look forward to his leveraging his 42 years of clinical and sales and marketing experience in the healthcare industry, including over 38 years spent working with energy-based surgical devices using radio frequency (RF) and ultrasonic energy.” said Gary Henley, Chairman of BioFuse Medical Technologies. “Mr. Sanders will be instrumental in both establishing and implementing our strategic plans to move BioFuse forward with the development of the proprietary tissue welding technology.”
Scott Sanders prior to joining BioFuse, lead key strategic developments in senior executive positions for more than 21 years at Olympus Corporation and Gyrus ACMI. He was responsible for directing activities of all electrosurgical products, marketing and salesforce & surgeon clinical training worldwide. . He also assisted in the creation and implementation of Olympus’s RF product development, reimbursement strategies, and procedure development. He launched revolutionary technologies of the PK Generator and instrumentation to The Thunderbeat system which combines bipolar RF energy with ultrasonics.
Mr. Sanders is quoted as saying: “I know this RF/Ultrasonic medical device space. I’ve been working in it at a leadership level for over 30-years. The ability to replace foreign-body staple and sutures with BioFuse’s RF tissue welding is the next revolution in surgical technology. I’m proud to be given the opportunity to launch this technology and change the way surgery is performed.”
Mr. Sanders also has conducted over 300 animal labs, open, laparoscopic, and single port approaches used to develop and perfect product development of RF and Ultrasonic instrumentation. He is the only non-surgeon who was granted privileges to conduct animal labs at Beaumont Hospital in Dublin, Ireland by the Royal College of Surgeons Ireland.
Beginning in 2011, he served as Executive Director of Clinical Marketing of Olympus’s global surgical energy group, coordinating the company’s product development plans, and providing clinical training and support for its global salesforce and physician customer base.
Mr. Sanders started his career working 13 years at Pfizer Valleylab (now Medtronic) in a variety of sales and marketing positions of increasing responsibility, culminating as the Director of Corporate Sales.
Most recently Mr. Sanders was with Apyx Medical (formerly Bovie Medical) as the Director of Clinical Education and Market Development.
Mr. Sanders holds a bachelor’s degree in Biology with minors in Chemistry, Physics and Mathematics from the University of Denver.
To learn more about BioFuse Medical, visit biofusemedical.com.
About BioFuse Medical Technologies, Inc.
BioFuse™ is a new RF tissue sealing and welding technology. Using transformative technology, proven in Europe in thousands of cases, this surgical innovation replaces traditional methods of sutures, staples, and electrosurgical vessel sealing. BioFuse technology can address a broad range of clinical applications, includes a robust pipeline of products in various stages of development, and has an FDA 510k clearance for vessel sealing, solid IP protection, and an arsenal of trade secrets.
This technology will serve a large and growing target market of $3 billion. Market Data indicates a strong and growing demand for advanced, innovative devices that facilitate evolving surgical procedural techniques and vastly improve patient outcomes. Surgeons are looking for new solutions, the new technology that will eliminate scars and lower infection rates.
BioFuse is privately held and interested accredited investors may learn more about investment opportunities in the Company’s 506© offering by visiting: biofusemedical.com.
SurgiFuse® is the core technology developed by BioFuse Medical Technologies. It is an advanced high-frequency electrosurgical system available and incorporates a unique and proprietary way of controlling and delivering energy to and through the target tissue. In studies, SurgiFuse® tissue fusion has been shown to be stronger than mechanical closure, creates a continuous seam in the tissue, and leaves no foreign bodies behind. SurgiFuse® encompasses the proprietary use of low voltages and high currents, optimized specifically for the tissue to be fused. In addition, energy output to the tissue occurs in pulses. These computer-controlled energy pulses create optimal temperatures that unravel large molecules in the tissue and as these molecules cool, they become intertwined and create a fusion. For more information on BioFuse please visit BioFuseMedical.com.
Gary Henley, Chairman
BioFuse Medical Technologies, Inc.
SOURCE: BioFuse Medical Technologies, Inc.
View source version on accesswire.com: